Currently, VCEL's 12-month EPS stands at $0.66, according to the most recent financial reports. Vericel's earnings per share in 2025 was reported at $0.33, marking a rise from $0.21 in 2024. VCEL recorded an EPS of $0.28 for the quarterly period ending on Sep 30, 2026.
In 2025, Vericel's earnings per share was $0.33, a rise of 57.1% from $0.21 in 2024. The quarterly earnings per share for the period ending Sep 30, 2026, was $0.28, showing a 180% increase compared to the same quarter last year. The trailing twelve months EPS for VCEL is $0.66 as of September 2026. Vericel's full-year EPS for 2024 was $0.21, a 400% rise compared to the previous year.
In the past 12 months, Vericel has recorded an earnings per share growth rate of 180% (YoY, quarterly). In the last five years, the company had an average annual EPS growth of 40.6%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| RPRX Royalty Pharma plc - Class A | 44.79 | -6.8% | 161.6% | 6.3% |
| VCEL Vericel Corp | 87.09 | 57.1% | N/A | 40.6% |
| NEOG Neogen Corp | N/A | 99.2% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.